Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 + Niraparib in Solid Tumors
NCT06161493Phase 1Withdrawn
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in solid tumor and ovarian cancer. Primary endpoints: Treatment-related Adverse Events and Serious Adverse Events up to 36 months and Maximum Tolerated Dose / Recommended Phase 2 Dose up to 12 months. Planned start Jan 2024; status: withdrawn.
02
Drugs
ZEN3694
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT06161493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161493.